Abstract
Options for modification of lipoprotein metabolism and, thus, for reduction of atherothrombotic complication have widened over recent years. Apart from the development of novel approaches new pharmacological formulations of common lipid lowering drugs have been prepared- e.g. statin-containing nanoparticles, fibrate nanoparticles, fixeddose combination withlipid-lowering drugs etc.
Clinical trials of therapies targeting HDL particle metabolism are being in progress despite we have not gathered any unambiguous evidence of positive effect of the CETP inhibitors or apoA1 mimetics on the progression of atherosclerosis so far. Brand new approaches in the treatment of dyslipidemia including MTP and PCSK9 inhibition or therapies utilizing anti-sense technologies rapidly accumulate evidence from clinical studies.
We have already learned about their lipid-modifying efficacy, however, first data documenting their impact atherosclerosis progression and cardiovascular risk suggest a promising future for these new drugs. Moreover, research laboratories continue working on novel options for lipoprotein metabolism modification (e.g.
LCAT or FDF21 replacement therapies). Not all the novel concepts will make it to clinical use but our therapeutic options in the management of dyslipidemia will definitely expand.